Literature DB >> 26899324

[Research advances of K-ras mutation in the prognosis and targeted therapy of gastric cancer].

Y Huang1, J Wei, B R Liu.   

Abstract

K-ras mutations have been described in 30% of human cancers with significantly different mutation frequencies. High K-ras mutation frequency is found in many cancers such as pancreas and lung cancers, whereas, gastric cancer has a relatively low K-ras mutation frequency. In recent years, numerous researches have focused on the K-ras mutation in gastric cancer. This review summarizes the K-ras mutation frequency in gastric cancer, the relationship of K-ras mutation with clinicopathologic features and prognosis of gastric cancer patients, targeted therapy for K-ras mutated gastric cancer, some small-molecular inhibitors of K-ras, and development of targeted therapy drugs for K-ras signaling pathway in gastric cancer.

Entities:  

Mesh:

Year:  2016        PMID: 26899324     DOI: 10.3760/cma.j.issn.0253-3766.2016.02.001

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  2 in total

1.  Knockdown of RREB1 inhibits cell proliferation via enhanced p16 expression in gastric cancer.

Authors:  Qi Gao; Yunhua Wu; Chaoxiang Lu; Wang Kai; Weike Xie; Qi Wang; Lei Wang; Shiqi Liu; Yongkang Pan
Journal:  Cell Cycle       Date:  2021-10-19       Impact factor: 5.173

2.  Suppression of Heterogeneous Nuclear Ribonucleoprotein C Inhibit Hepatocellular Carcinoma Proliferation, Migration, and Invasion via Ras/MAPK Signaling Pathway.

Authors:  Jiejun Hu; Dong Cai; Zhibo Zhao; Guo-Chao Zhong; Jianping Gong
Journal:  Front Oncol       Date:  2021-04-16       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.